A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines

被引:18
|
作者
Bandrick, Meggan [1 ]
Balasch, Monica [2 ]
Heinz, Andrea [1 ]
Taylor, Lucas [1 ]
King, Vickie [1 ]
Toepfer, Jeri [1 ]
Foss, Dennis [1 ]
机构
[1] Zoetis Inc, Vet Med Res & Dev, 333 Portage St, Kalamazoo, MI 49007 USA
[2] Zoetis Mfg & Res Spain SL, Ctra Camprodon S-N, Finca La Riba 17813, Vall De Bianya, Spain
关键词
PCV2; vaccine; evolution of virus strains; genotypes; cross-protection; CAPSID PROTEIN; PIGS; 2B; CHALLENGE; INFECTION; GENOTYPES; IMMUNITY; REVEALS; DISEASE; FARMS;
D O I
10.1186/s13567-022-01029-w
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Recent publications suggest PCV2 vaccine-induced protection is superior when the vaccine and challenge are closely matched. PCV2's evolutionary rate, propensity for recombination, and genotype shifting, all provide rationale for modernizing PCV2 vaccines. One mechanism to increase a vaccine's epitope breadth is by designing a bivalent vaccine. The objective of these studies was to evaluate efficacy of a monovalent (PCV1-2 chimera, cPCV2a or cPCV2b) and bivalent (cPCV2a-cPCV2b) vaccine in terms of homologous and heterologous efficacy. In Study A, pigs were vaccinated with cPCV2a or saline and challenged with PCV2a or PCV2b. In Study B, pigs were vaccinated with cPCV2a, cPCV2a-cPCV2b bivalent, or saline, and challenged with PCV2a. In Study C, pigs were vaccinated with cPCV2b, cPCV2a-cPCV2b bivalent, or saline, and challenged with PCV2b. In all studies vaccines and saline were administered intramuscularly to pigs at three to four weeks of age. Virulent PCV2b or PCV2a was administered to all animals approximately three weeks post-vaccination. Both mono and bivalent vaccinated groups demonstrated significantly lower viremia, percent of animals ever viremic, percent of animals with lymphoid depletion and/or histiocytic replacement, and percent of animals with PCV2 colonization of lymphoid tissues compared to saline controls. In Study A, a biologically relevant, though not significantly different, improvement in homologous versus heterologous protection was observed. In Studies B and C, biologically superior efficacy of the bivalent cPCV2a-cPCV2b vaccine compared to either monovalent vaccine was demonstrated. Taken together, cross-protection among mismatched PCV2 vaccine and challenge genotypes is not 100%; a bivalent PCV2 vaccine may provide the best opportunity to broaden coverage to circulating strains of PCV2.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Detection of porcine circovirus type 2 (PCV2) in the Philippines and the complexity of PCV2-associated disease diagnosis
    Agnes dela Cruz
    Chiara Palmieri
    Rachel Azul
    Christina Legaspi
    Suzan Lola
    Tamsin S. Barnes
    Christopher R. Parke
    Conny Turni
    John I. Alawneh
    Augusto S. Baluyut
    Voltaire G. Basinang
    Jose E. David
    Ronilo O. de Castro
    Ronnie Domingo
    Emmanuel Francisco
    Corazon Ignacio
    Eduardo L. Lapuz
    Milagros R. Mananggit
    Lilia Retes
    Edwin C. Villar
    Patrick J. Blackall
    Joanne Meers
    Tropical Animal Health and Production, 2021, 53
  • [32] Nontransmission of porcine circovirus 2 (PCV2) by embryo transfer
    Bielanski, A.
    Algire, J.
    Lalonde, A.
    Garceac, A.
    Pollard, J. W.
    Plante, C.
    THERIOGENOLOGY, 2013, 80 (02) : 77 - 83
  • [33] A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs
    Fenaux, M
    Opriessnig, T
    Halbur, PG
    Elvinger, F
    Meng, XJ
    JOURNAL OF VIROLOGY, 2004, 78 (12) : 6297 - 6303
  • [34] First evidence of Porcine Circovirus 2 (PCV2) in Slovakia
    Pistl, Jutaj
    Novackova, Michaela
    Jackova, Anna
    Pollakova, Jana
    Levkut, Mikulas
    Vilcek, Stefan
    DEUTSCHE TIERARZTLICHE WOCHENSCHRIFT, 2009, 116 (01): : 19 - 23
  • [35] Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b
    Jeong, Jiwoon
    Park, Changhoon
    Choi, Kyuhyung
    Chae, Chanhee
    VETERINARY MICROBIOLOGY, 2015, 177 (1-2) : 43 - 52
  • [36] Development of a differential multiplex real-time PCR assay for porcine circovirus type 2 (PCV2) genotypes PCV2a, PCV2b and PCV2d
    Wang, Yin
    Noll, Lance
    Porter, Elizabeth
    Stoy, Colin
    Dong, Junsheng
    Anderson, Joe
    Fu, Jinping
    Pogranichniy, Roman
    Woodworth, Jason
    Peddireddi, Lalitha
    Bai, Jianfa
    JOURNAL OF VIROLOGICAL METHODS, 2020, 286
  • [37] A Host Factor GPNMB Restricts Porcine Circovirus Type 2 (PCV2) Replication and Interacts With PCV2 ORF5 Protein
    Guo, Kangkang
    Xu, Lei
    Wu, Mengmeng
    Hou, Yufeng
    Jiang, Yanfen
    Lv, Jiangman
    Xu, Panpan
    Fan, Zhixin
    Zhang, Ruiqi
    Xing, Fushan
    Zhang, Yanming
    FRONTIERS IN MICROBIOLOGY, 2019, 9
  • [38] Influence of maternal antibodies on efficacy of porcine circovirus type 2 (PCV2) vaccination to protect pigs from experimental infection with PCV2
    Opriessnig, T.
    Patterson, A. R.
    Elsener, J.
    Meng, X. J.
    Halbur, P. G.
    CLINICAL AND VACCINE IMMUNOLOGY, 2008, 15 (03) : 397 - 401
  • [39] Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge
    Seo, Hwi Won
    Oh, Yeonsu
    Han, Kiwon
    Park, Changhoon
    Chae, Chanhee
    BMC VETERINARY RESEARCH, 2012, 8 : 1 - 9
  • [40] Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge
    Hwi Won Seo
    Yeonsu Oh
    Kiwon Han
    Changhoon Park
    Chanhee Chae
    BMC Veterinary Research, 8